BRNS (Barinthus Biotherapeutics) ROCE %: -26.32% (As of Mar. 2026)


BRNS Barinthus Biotherapeutics PLC BRNS
52 GF Score
Price $0.70
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics ROCE %?

Barinthus Biotherapeutics BRNS +2.94% 52 ROCE % is -26.32% as of Mar. 2026. GuruFocus rates BRNS with a GF Score™ of 52/100 and a GF Value™ of $1.12 (Possible Value Trap). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Barinthus Biotherapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -26.32%.

Barinthus Biotherapeutics  (NAS:BRNS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Barinthus Biotherapeutics ROCE % Related Terms

Barinthus Biotherapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics ROCE % Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -31.01 0.33 -33.27 -35.30 -57.20

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.28 -68.51 -54.37 -47.80 -26.32
BRNS
52GF Score
Barinthus Biotherapeutics PLC BRNS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics ROCE % Calculation

Barinthus Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-66.582/( ( (160.327 - 15.657) + (98.169 - 10.018) )/ 2 )
=-66.582/( (144.67+88.151)/ 2 )
=-66.582/116.4105
=-57.20 %

Barinthus Biotherapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-22.148/( ( (98.169 - 10.018) + (92.143 - 12.001) )/ 2 )
=-22.148/( ( 88.151 + 80.142 )/ 2 )
=-22.148/84.1465
=-26.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -26.32% mean?
Barinthus Biotherapeutics (BRNS) has a ROCE % of -26.32% as of Mar. 2026.
Is Barinthus Biotherapeutics' ROCE % too high?
Barinthus Biotherapeutics' current ROCE % is -26.32%. Overall, Barinthus Biotherapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' ROCE % compare to KYNB and SER?
Barinthus Biotherapeutics' ROCE % of -26.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Barinthus Biotherapeutics's current ROCE % is -26.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.70 — trading 37.5% below its estimated fair value. The current ROCE % is -26.32%. Barinthus Biotherapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current ROCE % is -26.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 37.5% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • ROCE %: -26.32%
  • GF Value™: $1.12 vs. price of $0.70 (37.5% below fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score

Get the complete analysis for BRNS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$1.12
GF Value